BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8180014)

  • 1. Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
    Ma J; Verweij J; Kolker HJ; van Ingen HE; Stoter G; Schellens JH
    Br J Cancer; 1994 May; 69(5):858-62. PubMed ID: 8180014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
    van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
    Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
    Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
    Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
    Chi KH; Kunugi KA; Kinsella TJ
    Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
    Los G; van Vugt MJ; den Engelse L; Pinedo HM
    Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
    Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
    Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
    Ma J; Maliepaard M; Kolker HJ; Verweij J; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(3):186-92. PubMed ID: 9443634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
    Hospers GA; de Vries EG; Mulder NH
    Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.
    Sark MW; Timmer-Bosscha H; Meijer C; Uges DR; Sluiter WJ; Peters WH; Mulder NH; de Vries EG
    Br J Cancer; 1995 Apr; 71(4):684-90. PubMed ID: 7710929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cisplatin on cell death and DNA crosslinking in rat mammary. Adenocarcinoma in vitro.
    Yamamoto J; Miyagi Y; Kawanishi K; Yamada S; Miyagi Y; Kodama J; Yoshinouchi M; Kudo T
    Acta Med Okayama; 1999 Oct; 53(5):201-8. PubMed ID: 10561728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
    Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
    Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.
    Gomi K; Ohno H; Nomura K; Okabe M; Kobayashi K; Niitani H
    Jpn J Cancer Res; 1992 May; 83(5):532-9. PubMed ID: 1618703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
    Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
    Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
    Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endovascular lung perfusion using high-dose cisplatin: uptake and DNA adduct formation in an animal model.
    Brown DB; Ma MK; Battafarano RJ; Naidu S; Pluim D; Zamboni WC; McLeod HL
    Oncol Rep; 2004 Jan; 11(1):237-43. PubMed ID: 14654932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.